Literature DB >> 34328516

Adolescent cannabinoid exposure modulates the vulnerability to cocaine-induced conditioned place preference and DNMT3a expression in the prefrontal cortex in Swiss mice.

P H Gobira1, A L Roncalho2, N R Silva3, G P Silote2, A J Sales3, S R Joca4,5.   

Abstract

RATIONALE: Cannabis sativa is the most widely used drug by adolescents globally. The recreational use of synthetic cannabinoids by teenagers has also grown in recent years. Despite the wrong perception that exposure to these drugs does not cause harm, repeated exposure to cannabinoids at early stages of life compromises important maturation processes and brain development. Chronic early cannabinoid use has been related to a higher risk of psychiatric outcomes, including cocaine addiction. Evidence suggests that exposure to natural and synthetic cannabinoids during adolescence modifies molecular and behavioral effects of cocaine in adulthood. Responses to cocaine are regulated by epigenetic mechanisms, such as DNA methylation, in the brain's reward regions. However, the involvement of these processes in modulation of the vulnerability to the effects of cocaine induced by prior exposure to cannabinoids remains poorly understood.
OBJECTIVES: Investigate whether exposure to the synthetic cannabinoid WIN55,212-2 during adolescence modulates anxiety- and depression-like behavior, memory, and cocaine reward in adult mice. We also evaluated whether exposure to cannabinoids during adolescence modulates the expression of enzymes that are involved in DNA methylation.
RESULTS: Exposure to WIN55,212-2 during adolescence did not alter anxiety- or depressive-like behavior. However, prior exposure to cannabinoids inhibited cocaine-induced conditioned place preference without modulating cocaine-induced hyperlocomotion, accompanied by an increase in expression of the enzyme DNA methyltransferase 3a (DNMT3a) in the prefrontal cortex.
CONCLUSIONS: Our findings suggest that exposure to WIN55,212-2 during adolescence leads to changes in DNMT3a expression, and this pathway appears to be relevant to modulating the rewarding effects of cocaine.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Cannabinoids; Adolescence; Cocaine; DNA methylation; DNMT3a; Epigenetic

Year:  2021        PMID: 34328516     DOI: 10.1007/s00213-021-05926-4

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  59 in total

1.  Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition.

Authors:  C S Breivogel; S R Childers
Journal:  J Pharmacol Exp Ther       Date:  2000-10       Impact factor: 4.030

2.  BDNF-TRKB signaling system of the dorsal periaqueductal gray matter is implicated in the panicolytic-like effect of antidepressant drugs.

Authors:  Plinio C Casarotto; Paula C dos Santos; Guilherme A Lucas; Caroline Biojone; Roger L H Pobbe; Heloisa H Vilela-Costa; Samia R L Joca; Francisco S Guimarães; Hélio Zangrossi
Journal:  Eur Neuropsychopharmacol       Date:  2015-03-17       Impact factor: 4.600

3.  Strain dependence of adolescent Cannabis influence on heroin reward and mesolimbic dopamine transmission in adult Lewis and Fischer 344 rats.

Authors:  Cristina Cadoni; Nicola Simola; Elena Espa; Sandro Fenu; Gaetano Di Chiara
Journal:  Addict Biol       Date:  2013-08-20       Impact factor: 4.280

4.  Permeation of WIN 55,212-2, a potent cannabinoid receptor agonist, across human tracheo-bronchial tissue in vitro and rat nasal epithelium in vivo.

Authors:  Remigius U Agu; Satyanarayana Valiveti; Kalpana S Paudel; Mitch Klausner; Patrick J Hayden; Audra L Stinchcomb
Journal:  J Pharm Pharmacol       Date:  2006-11       Impact factor: 3.765

5.  Cannabinoids ameliorate impairments induced by chronic stress to synaptic plasticity and short-term memory.

Authors:  Hila Abush; Irit Akirav
Journal:  Neuropsychopharmacology       Date:  2013-02-20       Impact factor: 7.853

6.  Chronic exposure to cannabinoids during adolescence but not during adulthood impairs emotional behaviour and monoaminergic neurotransmission.

Authors:  Francis Rodriguez Bambico; Nhu-Tram Nguyen; Noam Katz; Gabriella Gobbi
Journal:  Neurobiol Dis       Date:  2009-12-05       Impact factor: 5.996

7.  Distinct roles for the deacetylase domain of HDAC3 in the hippocampus and medial prefrontal cortex in the formation and extinction of memory.

Authors:  Yasaman Alaghband; Janine L Kwapis; Alberto J López; André O White; Osasumwen V Aimiuwu; Amni Al-Kachak; Kasuni K Bodinayake; Nicole C Oparaugo; Richard Dang; Mariam Astarabadi; Dina P Matheos; Marcelo A Wood
Journal:  Neurobiol Learn Mem       Date:  2017-09-08       Impact factor: 2.877

8.  Sex-dependent effects of periadolescent exposure to the cannabinoid agonist CP-55,940 on morphine self-administration behaviour and the endogenous opioid system.

Authors:  Miguel Biscaia; Beatriz Fernández; Alejandro Higuera-Matas; Miguel Miguéns; Maria-Paz Viveros; Carmen García-Lecumberri; Emilio Ambrosio
Journal:  Neuropharmacology       Date:  2008-02-01       Impact factor: 5.250

Review 9.  Animal models of anxiety disorders and stress.

Authors:  Alline C Campos; Manoela V Fogaça; Daniele C Aguiar; Francisco S Guimarães
Journal:  Braz J Psychiatry       Date:  2013       Impact factor: 2.697

Review 10.  Cannabis Use during Adolescent Development: Susceptibility to Psychiatric Illness.

Authors:  Benjamin Chadwick; Michael L Miller; Yasmin L Hurd
Journal:  Front Psychiatry       Date:  2013-10-14       Impact factor: 4.157

View more
  1 in total

Review 1.  Epigenetic Studies for Evaluation of NPS Toxicity: Focus on Synthetic Cannabinoids and Cathinones.

Authors:  Leila Mazdai; Matteo Fabbri; Micaela Tirri; Giorgia Corli; Raffaella Arfè; Beatrice Marchetti; Sabrine Bilel; Eva Bergamin; Rosa Maria Gaudio; Michele Rubini; Fabio De-Giorgio; Matteo Marti
Journal:  Biomedicines       Date:  2022-06-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.